Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to $28 from $27 and keeps an Outperform rating on the shares. Ekterly has seen robust early demand with 460 patient start forms which represents about $31M in potential revenue, but all patients get 4 doses of free drug and realization of that revenue depends on having and treating attacks and payer access, the analyst tells investors in a research note. The firm adds that consensus estimates near-term will be “unreliable” as KalVista is changing its fiscal year reporting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
- Promising Market Penetration and Growth Potential for KalVista Pharmaceuticals’ Ekterly
- KalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY Success
- Promising Outlook for KalVista Pharmaceuticals: Buy Rating Justified by Strong Launch Metrics and Strategic Initiatives for Ekterly
- Morning Movers: Kroger rises following second quarter results